BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1

BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1

Item
http://www.wikidata.org/entity/Q34048020
Fragment-Based Drug Discovery in the Bromodomain and Extra-Terminal Domain Family.Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells.Natural Killer Cell Response to Chemotherapy-Stressed Cancer Cells: Role in Tumor Immunosurveillance.PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?BRD4 profiling identifies critical Chronic Lymphocytic Leukemia oncogenic circuits and reveals sensitivity to PLX51107, a novel structurally distinct BET inhibitor.Modulation of antitumor immunity with histone deacetylase inhibitors.Chromatin dependencies in cancer and inflammation.Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway.BET proteins in abnormal metabolism, inflammation, and the breast cancer microenvironment.Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment.Plk1 inhibition enhances the efficacy of BET epigenetic reader blockade in castration-resistant prostate cancer.The MYC oncogene is a global regulator of the immune response.Bromodomain protein BRD4 inhibitor JQ1 regulates potential prognostic molecules in advanced renal cell carcinoma.Modeling combination therapy for breast cancer with BET and immune checkpoint inhibitorsLudwig Boltzmann Cluster Oncology (LBC ONC): first 10 years and future perspectivesInterplay between interferon regulatory factor 1 and BRD4 in the regulation of PD-L1 in pancreatic stellate cells
P2860

BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1

Item
http://www.wikidata.org/entity/Q34048020
description
2017 nî lūn-bûn
@nan
2017 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
BET-Bromodomain Inhibitors Eng ...... Immune Checkpoint Ligand PD-L1
@ast
BET-Bromodomain Inhibitors Eng ...... Immune Checkpoint Ligand PD-L1
@en
BET-Bromodomain Inhibitors Eng ...... Immune Checkpoint Ligand PD-L1
@nl
type
label
BET-Bromodomain Inhibitors Eng ...... Immune Checkpoint Ligand PD-L1
@ast
BET-Bromodomain Inhibitors Eng ...... Immune Checkpoint Ligand PD-L1
@en
BET-Bromodomain Inhibitors Eng ...... Immune Checkpoint Ligand PD-L1
@nl
prefLabel
BET-Bromodomain Inhibitors Eng ...... Immune Checkpoint Ligand PD-L1
@ast
BET-Bromodomain Inhibitors Eng ...... Immune Checkpoint Ligand PD-L1
@en
BET-Bromodomain Inhibitors Eng ...... Immune Checkpoint Ligand PD-L1
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P932
P356
P1433
P1476
BET-Bromodomain Inhibitors Eng ...... Immune Checkpoint Ligand PD-L1
@en
P2093
P2860
P304
P31
P356
10.1016/J.CELREP.2017.02.011
P433
P478
P50
P577
P698
P932